Angiotensin blockade in diabetic patients decreases insulin resistance-associated low-grade inflammation

European Journal of Clinical Investigation

Volumn 41, Issue 6, 2011, Pages 652-658

  Pavlatou, Maria G ^a   Mastorakos, George ^a   Margeli, Alexandra ^b   Kouskouni, Evangelia ^a   Tentolouris, Nicholas ^a   Katsilambros, Nikos ^a   Chrousos, George P ^a   Papassotiriou, Ioannis ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Angiotensin II; Angiotensin receptor blockers; Diabetes mellitus type 2; Insulin resistance; Interleukin 6

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; C REACTIVE PROTEIN; CANDESARTAN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINALYSIS;

ADULT; AGED; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONISTS; BENZIMIDAZOLES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; MIDDLE AGED; REGRESSION ANALYSIS; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 79955581558     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02453.x     Document Type: Article

References (46)

1. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-23.
2. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003;52:1799-805.
3. Crook M. Type II diabetes mellitus: a disease of the innate immune system? An update. Diabet Med 2003;21:203-7.
4. Mohamed-Ali V, Flower L, Sethi J, Hotamisligil G, Gray R, Humphries SE et al. beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies J Clin Endocrinol Metab 2001;86:5864-9.
5. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
6. Westerbacka J, Cornér A, Kolak M, Makkonen J, Turpeinen U, Hamsten A et al. Insulin regulation of MCP-1 in human adipose tissue of obese and lean women. Am J Physiol Endocrinol Metab 2008;294:E841-5.
7. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
8. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000;101:1372-8.
9. Nickenig G, Harrison DG. The AT (1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT (1) receptor regulation. Circulation 2002;105:530-6.
10. Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002;22:1257-66.
11. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 2002;82:S12-22.
12. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 2007;30(Suppl 1):S4-41.
13. Pavlatou MG, Mastorakos G, Lekakis I, Liatis S, Vamvakou G, Zoumakis E et al. Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results. Stress 2008;11:62-72.
14. Graham TE, Wason CJ, Bluher M, Kahn BB. Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects. Diabetologia 2007;50:814-23.
15. Persson F, Rossing P, Hovind P, Stehouwer CD, Schalkwijk C, Tarnow L et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes 2006;55:3550-5.
16. Lindholm LH, Dahlöf B, Edelman JM, Ibsen H, Borch-Johnsen K, Olsen MH et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003;362:619-20.
17. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003;35:881-900.
18. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005;16:120-6.
19. Schieffer B, Bünte C, Witte J, Hoeper K, Böger RH, Schwedhelm E et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004;44:362-8.
20. Schmieder SE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005;18:720-30.
21. Takemori K, Ito H, Suzuki T. Effects of the AT1 receptor antagonist on adhesion molecule expression in leukocytes and brain microvessels of stroke-prone spontaneously hypertensive rats. Am J Hypertens 2000;13:1233-41.
22. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
23. Benicky J, Sánchez-Lemus E, Pavel J, Saavedra JM. Anti-Inflammatory Effects of Angiotensin Receptor Blockers in the Brain and the Periphery. Cell Mol Neurobiol 2009;29:781-92.
24. Pérez-Castrillón JL, Silva J, Justo I, Sanz A, Martín-Luquero M, Igea R et al. Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. Am J Hypertens 2003;16:453-9.
25. Tu X, Chen X, Xie Y, Shi S, Wang J, Chen Y et al. Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury. J Am Soc Nephrol 2008;19:77-83.
26. Yoshiji H, Noguchi R, Ikenaka Y, Kitade M, Kaji K, Tsujimoto T et al. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. Curr Med Chem 2007;14:2749-54.
27. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging 2001;22:541-6.
28. Yu C, Gong R, Rifai A, Tolbert EM, Dworkin LD. Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. J Am Soc Nephrol 2007;18:750-9.
29. Chan YC, Leung PS. Angiotensin II type 1 receptor-dependent nuclear factor-kappaB activation-mediated proinflammatory actions in a rat model of obstructive acute pancreatitis. J Pharmacol Exp Ther 2007;323:10-8.
30. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905-10.
31. Ando H, Zhou J, Macova M, Imboden H, Saavedra JM. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 2004;35:1726-31.
32. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000;35:714-21.
33. Wassmann S, Hilgers S, Laufs U, Böhm M, Nickenig G. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002;22:1208-12.
34. Ridker PM, Danielson E, Rifai N, Glynn RJ; Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006; 48: 73-9. Epub 2006 May 19.
35. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
36. Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M. Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance. Diabetologia 2002;45:151.
37. Arnalich F, Hernanz A, López-Maderuelo D, Peña JM, Camacho J, Madero R et al. Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. Horm Metab Res 2000;32:407-12.
38. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B et al. Interleukin-1-receptor antagonist in type 2 Diabetes Mellitus. N Engl J Med 2007;356:1517-26.
39. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351-62. Review.
40. Tsigos C, Young RJ, White A. Diabetic neuropathy is associated with increased activity of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 1993;76:554-8.
41. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R et al. Candesartan effect on inflammation in hypertension. Hypertens Res 2010;33:209-13.
42. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552-63.
43. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the HARM-Overall programme. Lancet 2003; 362: 759-66. Erratum in: Lancet 2009; 9703: 1744.
44. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
45. The NAVIGATOR Study Group. Effects of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med 2010;362:1477-90.
46. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme Inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005;46:821-6.